

Steve Sisolak  
Governor  
Richard Whitley, MS  
Director



**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
*Helping people. It's who we are and what we do.*



Suzanne Bierman,  
JD MPH  
Administrator

---

**REVISED NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD**

**Date of Posting:** August 24, 2022  
**Date of Revision:** September 14, 2022

**Date of Meeting:** Thursday, September 22, 2022, at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Script Board.

**Place of Meeting:** The physical location of this meeting which is open to the public at:

Alexis Park Resort Hotel  
375 E Harmon Ave  
Las Vegas, NV, 89169  
702-796-3300

**Please check with staff to verify room location.**

Space is limited at the physical location and subject to any applicable social distancing or mask wearing requirements as may be in effect at the time of the meeting for the county in which the physical meeting is held.

*Note: If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email [rxinfo@dhcfp.nv.gov](mailto:rxinfo@dhcfp.nv.gov) and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.*

**Webinar:** [Sept SSSB Meeting](#)  
(See final agenda page for full link or employ the shortened link directly above)

OR

<https://tinyurl.com/dea4u369>

**Audio Only:** (417) 501-2485

Event Number: 569767419 #

**PLEASE DO NOT PUT THIS NUMBER ON HOLD** (*hang up and rejoin if you must take another call*)

**YOU MAY BE UNMUTED BY THE HOST WHEN SEEKING PUBLIC COMMENT, PLEASE HANG UP AND REJOIN IF YOU ARE HAVING SIDE CONVERSATIONS DURING THE MEETING**

**This meeting will be recorded to facilitate note-taking or other uses. By participating you consent to recording of your participation in this meeting.**

**Closed Executive Session – 1:00 PM**

**Open Session/Public Meeting – will begin upon completion of the Closed Executive Session**

### **AGENDA**

- 1. Call to Order and Roll Call**
- 2. General Public Comment**

*Public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to [rxinfo@dncfp.nv.gov](mailto:rxinfo@dncfp.nv.gov). There may be opportunity to take public comment via telephone or the meeting's virtual platform as well as in person opportunities, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comment may be limited to three minutes per person. **Note: this guidance applies for all periods of public comment referenced further in the agenda, such as those related to clinical presentations.***

Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(II).

- 3. Administrative**
  - a. **For Possible Action:** Review and Approve Updated Meeting Minutes from June 23, 2022.
  - b. Status Update by DHCFP.
  - c. Bylaws.
- 4. Annual Review – Established Drug Classes Being Reviewed Due to the Release of New Drugs**
  - a. **For Possible Action:** Discussion and possible adoption of Toxicology Agents- Antidotes, **Opiate Antagonists; Substance Abuse Agents**
    - i. Public comment.
    - ii. Drug class review presentation by MagellanRx.
    - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
    - iv. Presentation of recommendations for PDL inclusion by MagellanRx.

- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- b. **For Possible Action:** Discussion and possible adoption of **Immunomodulator: Atopic Dermatitis Biologic Response Modifiers—Targeted Immunomodulator**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
  - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
  - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- c. **For Possible Action:** Discussion and possible adoption Neurological Agents- **Alzheimer’s Agents, Cholinesterase Inhibitors, Antiparkinsonian Agents, Non-Ergot AgonistsAnticonvulsants**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
  - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
  - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- d. **For Possible Action:** Discussion and possible adoption of **Monoclonal Antibodies for the Treatment of Respiratory Conditions**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
  - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
  - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- e. **For Possible Action:** Discussion and possible adoption of Analgesics- Miscellaneous Analgesics, **Tramadol and Related Drugs**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
  - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
  - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- f. **For Possible Action:** Discussion and possible adoption of **Hormone and Hormone Modifiers – Pituitary Hormones, Growth Hormone Modifiers; Incretin Mimetics and CombinationsOphthalmic—Agents—Ophthalmics for Dry Eye Disease**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in

- class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

5. **Annual Review - ~~New Drug Classes for Proposed Addition~~ ~~Established Drug Classes Being Reviewed Due to the Release of New Generics~~**

a. **For Possible Action:** Discussion and possible adoption of **Biological Response Modifiers – Colony Stimulating Factors**~~Ophthalmic Agents – Ophthalmics for Dry Eye Disease~~

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

~~b. **For Possible Action:** Discussion and possible **Psychotropic Agents – Antidepressants, other**~~

- ~~i. **Public comment.**~~
- ~~ii. **Drug class review presentation by MagellanRx.**~~
- ~~iii. **Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.**~~
- ~~iv. **Presentation of recommendations for PDL inclusion by MagellanRx.**~~
- ~~v. **Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.**~~

6. **Annual review - Established Drug Classes with proposed changes**

a. **For Possible Action:** Discussion and possible adoption of **Biologic Response Modifiers – MS Agents, Oral Anti-infective agents**~~Anti-virals, Anti-herpetic agents, Influenza agents~~

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

b. **For Possible Action:** Discussion and possible adoption of **Gastrointestinal Agents – Proton Pump Inhibitors (PPIs)**~~Sympathomimetics~~

- i. Public comment.
- ii. Drug class review presentation by MagellanRx.
- iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
- iv. Presentation of recommendations for PDL inclusion by MagellanRx.
- v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.

- c. **For Possible Action:** Discussion and possible adoption of ~~Hormone and Hormone Modifiers - Androgens~~ **Biologic Response Modifiers Immunomodulators, Targeted Immunomodulators**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
  - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
  - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- d. **For Possible Action:** Discussion and possible adoption of ~~Neurological Agents – Anticonvulsants; Anti-Migraine Agents, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists, Serotonin-Receptor Agonists (Triptans)~~ **Cardiovascular Agents– Antihypertensive Agents, Angiotensin II Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, Calcium Channel Blockers; Antilipemics, Bile Acid Sequestrants; Omega-3 Fatty Acids**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
  - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
  - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- e. **For Possible Action:** Discussion and possible adoption of ~~Psychotropic Agents – Antipsychotics, Atypical Antipsychotics – Oral/Topical~~ **Dermatologic Agents– Antipsoriatic Agents; Topical Analgesics; Topical Anti-infectives, Acne Agents: Topical, Benzoyl Peroxide, Antibiotics, and Combination Products; Topical Anti-inflammatory Agents**
- i. Public comment.
  - ii. Drug class review presentation by MagellanRx.
  - iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.
  - iv. Presentation of recommendations for PDL inclusion by MagellanRx.
  - v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.
- ~~f. **For Possible Action:** Discussion and possible adoption of Electrolyte and Renal Agents– Phosphate Binding Agents~~
- ~~i. Public comment.~~
  - ~~ii. Drug class review presentation by MagellanRx.~~
  - ~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~
  - ~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~
  - ~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~

~~g. **For Possible Action:** Discussion and possible adoption of Gastrointestinal Agents—Antiulcer Agents, H2-Blockers, Proton Pump Inhibitors (PPIs); Functional Gastrointestinal Disorder Drugs; Gastrointestinal Anti-inflammatory Agents~~

~~i. Public comment.~~

~~ii. Drug class review presentation by MagellanRx.~~

~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~

~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~

~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~

~~h. **For Possible Action:** Discussion and possible adoption of Genitourinary Agents—Bladder Antispasmodics~~

~~i. Public comment.~~

~~ii. Drug class review presentation by MagellanRx.~~

~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~

~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~

~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~

~~i. **For Possible Action:** Discussion and possible adoption of Hormone and Hormone Modifiers—Antidiabetic Agents, Alpha-Glucosidase Inhibitors/Amylin analogs/Misc., Biguanides, Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin, Incretin Mimetics and Combinations, Meglitinides; Insulins, Rapid-Acting Insulins, Long-Acting Insulins, Pre-Mixed Insulin Combinations; Pituitary Hormones, Growth Hormone Modifiers; Progestins for Cachexia~~

~~i. Public comment.~~

~~ii. Drug class review presentation by MagellanRx.~~

~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~

~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~

~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~

~~j. **For Possible Action:** Discussion and possible adoption of Musculoskeletal Agents—Antigout Agents; Bone Resorption Inhibitors, Bisphosphonates, Nasal Calcitonins; Restless-Leg Syndrome Agents; Skeletal Muscle Relaxants~~

~~i. Public comment.~~

~~ii. Drug class review presentation by MagellanRx.~~

~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~

~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~

~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~

- ~~k. **For Possible Action:** Discussion and possible adoption of Neurological Agents—Alzheimer’s Agents, Cholinesterase Inhibitors; Antiparkinsonian Agents, Non-Ergot Dopamine Agonists~~
- ~~l. \_\_\_\_\_~~
- ~~m. Public comment.~~
- ~~n. Drug class review presentation by MagellanRx.~~
- ~~o. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~
- ~~p. Presentation of recommendations for PDL inclusion by MagellanRx.~~
- ~~q. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~
- ~~r. \_\_\_\_\_~~
- ~~s. **For Possible Action:** Discussion and possible adoption of Ophthalmic Agents—Antiglaucoma Agents; Ophthalmic Antihistamines; Ophthalmic Anti-infectives; Ophthalmic Anti-inflammatory Agents, Ophthalmic Corticosteroids, Ophthalmic Nonsteroidal Anti-inflammatory Drugs~~
- ~~t. \_\_\_\_\_~~
- ~~u. Public comment.~~
- ~~v. Drug class review presentation by MagellanRx.~~
- ~~w. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~
  - ~~iii. Presentation of recommendations for PDL inclusion by MagellanRx.~~
  - ~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~
- ~~x. **For Possible Action:** Discussion and possible adoption of Otic Agents—Otic Anti-infectives, Otic Quinolones~~
  - ~~i. Public comment.~~
  - ~~ii. Drug class review presentation by MagellanRx.~~
  - ~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~
  - ~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~
  - ~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~
- ~~y. **For Possible Action:** Discussion and possible adoption of Psychotropic Agents—ADHD Agents~~
  - ~~Selective Serotonin Reuptake Inhibitors; Antipsychotics, Atypical Antipsychotics—Oral/Topical; Anxiolytics, Sedatives, and Hypnotics~~
  - ~~i. Public comment.~~
  - ~~ii. Drug class review presentation by MagellanRx.~~
  - ~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~
  - ~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~
  - ~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~
- ~~z. **For Possible Action:** Discussion and possible adoption of Respiratory Agents—Nasal Antihistamines; Respiratory Anti-inflammatory Agents, Nasal Corticosteroids; Long-Acting /Maintenance Therapy, Long-Acting Beta Adrenergics~~

- ~~i. Public comment.~~
- ~~ii. Drug class review presentation by MagellanRx.~~
- ~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~
- ~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~
- ~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~

~~aa. **For Possible Action:** Discussion and possible adoption of Toxicology Agents- Substance Abuse Agents~~

- ~~i. Public comment.~~
- ~~ii. Drug class review presentation by MagellanRx.~~
- ~~iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.~~
- ~~iv. Presentation of recommendations for PDL inclusion by MagellanRx.~~
- ~~v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.~~

7. **Annual Review - Drug Classes Without Proposed Changes**

- a. Public Comment
- b. **For Possible Action:** Discussion and possible adoption of the Preferred Drug List (PDL) as presented by MagellanRx and the Division of Health Care Financing and Policy without changes.
  - i. Analgesics- ~~Miscellaneous Analgesics, Neuropathic Pain/Fibromyalgia~~; Opiate Agonists; Opiate Agonists- Abuse Deterrent; Non-Steroidal Anti- Inflammatory Drugs- Oral, **Neuropathic Pain/Fibromyalgia**.
  - ii. Antihistamines- H1 blockers- non-Sedating
  - iii. Anti-infective Agents- **Aminoglycosides**; Antivirals, Alpha Interferons, Anti-hepatitis Agents – Polymerase Inhibitors/Combination Products, Anti-hepatitis Agents – Ribavirin; Cephalosporins, Second-Generation, Third Generation; Macrolides; Quinolones, 2nd Generation, 3rd Generation **Inhaled Aminoglycosides**.
  - ~~iii-iv. Autonomic Agents – Self-Injectable Epinephrine.~~
  - ~~iv-v. Biologic Response Modifiers- Targeted Immunomodulators~~; Multiple Sclerosis Agents, Injectable, ~~Oral~~, Specific Symptomatic Treatment.
  - ~~v-vi. Cardiovascular Agents- Antihypertensive Agents, Angiotensin II Receptor Antagonists, Angiotension-Converting Enzyme Inhibitors, Beta-Blockers, Calcium-Channel Blockers, Vasodilators – Oral and Inhaled, Vasodilators – Oral; Antilipemics, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Statins, Niacin Agents; Miscellaneous Heart Failure Agents.~~
  - ~~vi-vii. Dermatological Agents- Acne Agents, Topical Antivirals, Antipsoriatic Agents, Topical Analgesics, Topical Anti-infectives, Impetigo Agents: Topical, Topical Antivirals, Topical Scabicides; Topical Anti-Inflammatory Agents, Immunomodulators Topics; Topical Antineoplastics, Topical Retinoids.~~
  - ~~vii-viii. Electrolytes and Renal Agents- Potassium Replacement Agents; Phosphate Binding Agents.~~
  - ~~viii. Electrolytic and Renal Agents, Phosphate Binding Agents, Potassium Removing Agents-~~
  - ix. Gastrointestinal Agents- Antiemetics, Pregnancy-induced Nausea and Vomiting Treatment, Serotonin-Receptor Antagonists/Combinations; Antiulcer Agents, H2 Blockers; **Gastrointestinal Anti-inflammatory Agents**; Gastrointestinal Enzymes; **Functional Gastrointestinal Disorder Drug**.
  - x. Genitourinary Agents- Benign Prostatic Hyperplasia Agents, 5-Alpha Reductase Inhibitors, Alpha-Blockers; **Bladder Antispasmodics**.
  - xi. Hematological Agents- Anticoagulants, Oral, Injectable; **Platelet Inhibitors**; Erythropoiesis-Stimulating Agents; **Platelet Inhibitors**



- xii. Hormones and Hormone Modifiers- Androgens; Antidiabetic Agents, Alpha Glucosidase Inhibitors/Amylin analogs/Mics, Biguanides, Dipeptidyl Peptidase 4 Inhibitors and Combinations with Metformin, Meglitinides, SGLT2 Inhibitors and Combinations, Sulfonylureas, Thiazolidinediones and Combinations; ~~Insulins, Anti-Hypoglycemic Agents; Insulins, Short-Intermediate Acting Insulins.~~
- ~~xii~~-xiii. Musculoskeletal Agents – Bone Resorption Inhibitors, Bisphosphonates, nasal Calcitonins; Restless leg Syndrome Agents; Skeletal Muscle Relaxants; Anti-Gout.
- ~~xiii~~-xiv. Neurological Agents- Alzheimer’s Agents, NMDA Receptor Antagonists; ~~Anticonvulsants~~, Barbiturates, Benzodiazepines, Hydantoins; ~~Antiparkinsonian Agents, Dopamine Precursor.~~ ~~Anti-Migraine Agents, Calcitonin Gene-Related Peptide Receptor Antagonists, Serotonin Receptor Agonists (Triptans); Antiparkinsonian Agents, Dopamine Precursors; Movement Disorders-~~
- xv. Ophthalmic Agents- Ophthalmic Anti-infectives, Ophthalmic Macrolides, Ophthalmic Anti-inflammatory agents, Ophthalmic Corticosteroids, Ophthalmic NSAIDs, Anti-glaucoma, Antihistamine, ~~Ophthalmic Quinolones; Ophthalmic Anti-infective, Anti-infective/Anti-inflammatory Combinations.~~
- ~~xiv~~-xvi. Otic Agents
- ~~xv~~-xvii. Psychotropic Agents- ADHD; ~~Selective-Serotonin Reuptake Inhibitors, Antidepressants other; Antipsychotics, Atypical Antipsychotics- Long Acting Injectables; Anxiolytics, Sedatives and Hypnotics; Psychostimulants,~~ Narcolepsy Agents.
- ~~xvi~~-xviii. Respiratory Agents- Respiratory ~~Antihistamines; Respiratory Anti-inflammatory Agents, Leukotriene Receptor Antagonists;~~ ~~Nasal Corticosteroids, Phosphodiesterase Type 4 Inhibitors; Long-acting/Maintenance Therapy, Glucocorticoids/Long-Acting Beta-2 Adrenergic Combination Products, Long-Acting Beta Adrenergics; Anticholinergics and Combination Products;~~ Short-Acting/Rescue Therapy, Ipratropium and Combinations; Long-Acting/Maintenance Therapy, Inhaled Glucocorticoids, Anticholinergics and Combination Products; Short-Acting/Rescue Therapy, Short-Acting Beta Adrenergic., ~~Ipratropium and Combinations.~~

~~8. Update to bylaws~~

- ~~a. Discussion by Board and action by Board for approval of bylaws.~~

8. MagellanRx Reports: New Drugs to Market and New Line Extensions

9. Closing Discussion

- a. Public comments on any subject.

(No action may be taken upon a matter raised under public comment period unless the matter itself has been specifically included on an agenda as an action item. Comments will be limited to three minutes per person. Persons making comment will be asked to begin by stating their name for the record and to spell their last name and provide the secretary with written comments.)

- b. **For Possible Action:** Date and location of the next meeting.
- c. Adjournment.

**PLEASE NOTE:**

Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to three minutes.

This notice and agenda have been posted online at <http://dhcfp.nv.gov> and <http://notice.nv.gov> as well as Carson City, Las

Vegas, and Reno central offices for the Division of Health Care Financing and Policy. Email notice has been made to such individuals as have requested notice of meetings (to request notifications please contact [rxinfo@dncfp.nv.gov](mailto:rxinfo@dncfp.nv.gov), or at 1100 East William Street, Suite 101, Carson City, Nevada 89701).

If you require a physical copy of supporting material for the public meeting, please contact [rxinfo@dncfp.nv.gov](mailto:rxinfo@dncfp.nv.gov), or at 1100 East William Street, Suite 101, Carson City, Nevada 89701). Limited copies of materials will also be available on site at the meeting's physical location. Supporting material will also be posted online at <http://dncfp.nv.gov/> and <https://nevadamedicaid.magellanrx.com/provider/drug-utilization-review>

**All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.**

**Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at [rxinfo@dncfp.nv.gov](mailto:rxinfo@dncfp.nv.gov) in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701.**

Full Microsoft Teams Link:

[https://teams.microsoft.com/l/meetup-join/19%3ameeting\\_NGVIODk4NWItOTZmMS00ZTM0LWl5M2UtMDFI0DU2MjBIMTdm%40thread.v2/0?context=%7b%22Tid%22%3a%22a9df4fcb-7f39-49f4-9d70-1ee81b27a772%22%2c%22Oid%22%3a%22f82de288-0b75-477a-bb57-eaaa4336060e%22%7d](https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGVIODk4NWItOTZmMS00ZTM0LWl5M2UtMDFI0DU2MjBIMTdm%40thread.v2/0?context=%7b%22Tid%22%3a%22a9df4fcb-7f39-49f4-9d70-1ee81b27a772%22%2c%22Oid%22%3a%22f82de288-0b75-477a-bb57-eaaa4336060e%22%7d)